Effectiveness of mepolizumab therapy in patients with severe eosinophilic asthma : Austrian real-life data
Copyright © 2020 Elsevier Ltd. All rights reserved..
BACKGROUND: Mepolizumab was effective in several randomized clinical trials (RCTs) in patients with severe eosinophilic asthma, but evidence for symptom control in a real-world population is scarce.
OBJECTIVE: To assess asthma symptom control, lung function, use of oral corticosteroids, and biomarkers after mepolizumab initiation in real-world clinical practice.
METHODS: Thirty-five adult patients with severe eosinophilic asthma and inadequate asthma symptom control, including former smokers and patients with cardiac disease, were enrolled in a prospective single-arm real-world study. Asthma control tests (ACT), exacerbations, spirometry (pre-bronchodilator forced expiratory volume in 1 s [FEV1]), and oral corticosteroid doses were documented. Further assessments included peripheral blood eosinophil counts and adverse events.
RESULTS: After mepolizumab initiation asthma symptom control was significantly improved with the median ACT score of 12.5 at baseline (interquartile range [IQR ]10.5-19.5) rising to 19 (15-22.5) after 4 weeks. The improvement was maintained throughout the observation period of 20 weeks. Likewise, exacerbations were reduced. After 8 weeks of mepolizumab daily OCS doses were reduced from 6.25 mg daily (0-20) at baseline to 2.5 mg daily (0-11.9) at week 8 (P < 0.001). FEV1 remained generally unchanged during the course of the study. Eosinophil counts rapidly declined and remained at a low level during the observation period. No new safety signals were observed in this study.
CONCLUSION: Mepolizumab improved asthma symptom control and had a steroid-sparing effect. Efficacy in this real-world study was comparable to RCTs, despite a history of smoking and comorbidities in many of the patients included.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:64 |
|---|---|
| Enthalten in: |
Pulmonary pharmacology & therapeutics - 64(2020) vom: 17. Okt., Seite 101946 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Renner, Andreas [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 17.09.2021 Date Revised 17.09.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.pupt.2020.101946 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM315210761 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM315210761 | ||
| 003 | DE-627 | ||
| 005 | 20231225154422.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.pupt.2020.101946 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1050.xml |
| 035 | |a (DE-627)NLM315210761 | ||
| 035 | |a (NLM)32949705 | ||
| 035 | |a (PII)S1094-5539(20)30150-4 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Renner, Andreas |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Effectiveness of mepolizumab therapy in patients with severe eosinophilic asthma |b Austrian real-life data |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 17.09.2021 | ||
| 500 | |a Date Revised 17.09.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2020 Elsevier Ltd. All rights reserved. | ||
| 520 | |a BACKGROUND: Mepolizumab was effective in several randomized clinical trials (RCTs) in patients with severe eosinophilic asthma, but evidence for symptom control in a real-world population is scarce | ||
| 520 | |a OBJECTIVE: To assess asthma symptom control, lung function, use of oral corticosteroids, and biomarkers after mepolizumab initiation in real-world clinical practice | ||
| 520 | |a METHODS: Thirty-five adult patients with severe eosinophilic asthma and inadequate asthma symptom control, including former smokers and patients with cardiac disease, were enrolled in a prospective single-arm real-world study. Asthma control tests (ACT), exacerbations, spirometry (pre-bronchodilator forced expiratory volume in 1 s [FEV1]), and oral corticosteroid doses were documented. Further assessments included peripheral blood eosinophil counts and adverse events | ||
| 520 | |a RESULTS: After mepolizumab initiation asthma symptom control was significantly improved with the median ACT score of 12.5 at baseline (interquartile range [IQR ]10.5-19.5) rising to 19 (15-22.5) after 4 weeks. The improvement was maintained throughout the observation period of 20 weeks. Likewise, exacerbations were reduced. After 8 weeks of mepolizumab daily OCS doses were reduced from 6.25 mg daily (0-20) at baseline to 2.5 mg daily (0-11.9) at week 8 (P < 0.001). FEV1 remained generally unchanged during the course of the study. Eosinophil counts rapidly declined and remained at a low level during the observation period. No new safety signals were observed in this study | ||
| 520 | |a CONCLUSION: Mepolizumab improved asthma symptom control and had a steroid-sparing effect. Efficacy in this real-world study was comparable to RCTs, despite a history of smoking and comorbidities in many of the patients included | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a ACT score | |
| 650 | 4 | |a Anti-IL-5 | |
| 650 | 4 | |a Asthma | |
| 650 | 4 | |a Asthma treatment | |
| 650 | 4 | |a Biomarker profile | |
| 650 | 4 | |a FEV1 | |
| 650 | 4 | |a Mepolizumab | |
| 650 | 4 | |a Real-world study | |
| 650 | 7 | |a Anti-Asthmatic Agents |2 NLM | |
| 650 | 7 | |a Antibodies, Monoclonal, Humanized |2 NLM | |
| 650 | 7 | |a mepolizumab |2 NLM | |
| 650 | 7 | |a 90Z2UF0E52 |2 NLM | |
| 700 | 1 | |a Marth, Katharina |e verfasserin |4 aut | |
| 700 | 1 | |a Patocka, Karin |e verfasserin |4 aut | |
| 700 | 1 | |a Idzko, Marco |e verfasserin |4 aut | |
| 700 | 1 | |a Pohl, Wolfgang |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Pulmonary pharmacology & therapeutics |d 1997 |g 64(2020) vom: 17. Okt., Seite 101946 |w (DE-627)NLM092899625 |x 1522-9629 |7 nnns |
| 773 | 1 | 8 | |g volume:64 |g year:2020 |g day:17 |g month:10 |g pages:101946 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.pupt.2020.101946 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 64 |j 2020 |b 17 |c 10 |h 101946 | ||